Mutual Pharma Sanctioned In Sulindac Suit

By Leigh Kamping-Carder

Law360, New York (November 04, 2009, 5:14 PM ET) -- Mutual Pharmaceutical Co. Inc. will have to produce records related to potential side effects of sulindac and four other drugs for withholding a decade's worth of regulatory reports in a suit alleging its prescription anti-inflammatory drug caused a potentially fatal skin disease.

Judge Joseph N. Laplante of the U.S. District Court for the District of New Hampshire granted sanctions against Mutual on Monday, although he found the drugmaker had acted in good faith and stopped short of awarding all the relief plaintiffs Karen L. Bartlett and...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles